Los Alamos National Laboratory Home PageSearch for people in the Lab's phone bookSearch the Laboratory's Web site
MESA wins R&D 100 Award

R&D 100 sealMESA: Measuring Enzyme-Substrate Affinities

 

MESA graphic
A fluorescing drug molecule (glowing gold oval) binds to a protein (twisted-and-coiled thin teal “rope”) within a “ribbon” representation of a bacterial ribosome, a frequent target for antibiotic drugs. This binding of the native drug to protein molecule would be unambiguously detected by MESA label-free measurement technology. The currently standard techniques, which rely on detecting a drug whose structure has been altered by an attached fluorescent label, might not detect the binding.

Edel
Postdoctoral researcher Edel Minogue binds proteins to a slide for analysis.

The MESA technology, developed in Chemistry Division, has the potential to revolutionize the way the pharmaceutical industry discovers and brings new drugs to market. This amazing technique has won a 2005 R&D 100 Award and is the core technology behind a new Los Alamos spin-off company, Caldera Pharmaceuticals Inc. Caldera will mature the technology and bring it to market.

MESA is a low-cost assay for detecting the binding of drugs to proteins (and other biomolecules and cell structures) without the biasing influence of added fluorescent molecular labels. The assay images drug-protein binding using atoms intrinsic to drug molecules themselves. Because of this label-free detection, MESA captures and quantitates all drug-protein binding, including bindings that are potentially therapeutic and those that are potentially toxic. This allows MESA measurements to generate a complete therapeutic index early in the drug-development process. Today’s high drug-development failure rate—the primary cause of the high cost of new drugs—is driven by the inability to measure more than an infinitesimal number of protein-drug interactions. It is estimated that the cost for fully developing a new drug is well over a billion dollars. MESA’s ability to measure a very large number of these interactions and its resulting early detection of toxicity could prevent the late stage clinical failures that consume up to 80% of pharmaceutical development costs.

Applications

Benefits

Comparison to state-of-the-art.

drug schematic
Many drugs like ziprasidone work by fitting into a cavity in a specific protein (light-blue spheroid). When drugs are labeled with compounds like fluorescein, they often no longer fit into a protein cavity (fluorescein-labeled ziprasidone, lower right) that would otherwise accommodate them (unlabeled ziprasidone, lower left); this yields false data and, therefore, compromises any data derived from the fluorescently labeled drug. By contrast, MESA uses the intrinsic features of many drugs to measure drug-protein binding.

 

Principal Developers: Benjamin Warner (C-SIC), George Havrilla (C-CSE), and Edel Minogue (C-SIC).

Graphics and text developed by IM-1. 7/05


 
C-ADI | C-AAC | C-PCS | C-INC | C-CSE | C-SIC | C-FM
 

   

The World's Greatest Science Protecting America
Operated by the University of California for the U.S. Department of Energy
Inside | Privacy Policy | Copyright © 1993-2005 UC | Web Contact

spacer spacer spacer spacer